Participant flow

Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms · Source last updated 2026-10-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   All eligible patients will receive up to 2 cycles of CPX-351 for remission induction. The CPX-351 dose for the first induction cycle is 100 units/m\^2 (corresponds to 44 mg/m\^2 daunorubicin and 100 mg/m\^2 cytarabine) on Days 1, 3 and 5. A second induction cycle at the same CPX-351 dose is administered on Days 1 and 3 for patients with CR/CRi but positive residual disease (MRD ≥0.1%) by flow cytometry. Patients attaining complete remission and MRD \< 0.1% could proceed to hematopoietic stem cell transplantation (HSCT). If HSCT cannot be performed within four weeks from the evaluation date (Day 22 of the first cycle), patients will receive a second course with lower doses of daunorubicin (29 mg/m\^2) and cytarabine (65 mg/m\^2).

   id

   FG000

   title

   CPX-351 (Vyxeos)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         25

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

All 25 patients with Secondary Myeloid Neoplasms (SMN) were eligible for the study.

recruitment Details

25 patients enrolled in St. Jude between 1/17/2023 and 7/24/2025.

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice